Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 ...Middle East

SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an...

Hence then, the article about inmagene and hutchmed announce first participants in global phase i trial of img 007 was published today ( Wednesday 06/07/2022 - 07:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 )

Also on site :

• Blackpink’s Jisoo to Receive Madame Figaro Rising Star Award at Canneseries
• Walmart's 'Beautiful' Midcentury Modern TV Stand 'Looks More Expensive Than It Is,' and It's Now Only $62
• Family sues ChatGPT-maker OpenAI over school shooting in Canada